InvestmentJun 10, 2026, 09:09 PM
Humacyte Prices $50M Public Offering at $1.05/Share
AI Summary
Humacyte, Inc. announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at $1.05 per share, aiming to raise $50 million in gross proceeds. The offering is expected to close around June 12, 2026, with underwriters also having an option for additional shares. The company intends to use the net proceeds to fund the commercialization of Symvess®, support a planned Biologics License Application supplement for a hemodialysis indication, advance its product pipeline, and for general corporate purposes.
Key Highlights
- Humacyte priced an underwritten public offering of 47,619,048 shares of common stock.
- The public offering price is $1.05 per share.
- The offering is expected to generate aggregate gross proceeds of $50 million.
- Underwriters have a 30-day option to purchase up to an additional 7,142,857 shares.
- Net proceeds will fund the commercialization of Symvess® and related BLA supplement filing.
- Proceeds will also support pipeline development, working capital, and general corporate purposes.
- The closing of the offering is expected on or about June 12, 2026.
Price Impact
More from HUMA